Introduction
and FBP1, have been reported to accumulate in parkin knockout mice as well as in sporadic PD subjects [16, 19] , whereas accumulation of ␣-Sp22 and CDC-rel 2 has been shown in parkin ARJP subjects [12, 20] . [21] . Considering these data, we investigated whether parkin is involved in regulation of PLC␥1, an enzyme known to be degraded in the proteasome following ubiquitination by the E3 ubiquitin ligase, c-Cbl [22] .
Parkin ubiquitination of the substrate Eps15 lead to regulation of the epidermal growth factor receptor (EGFR). Lack of parkin results in enhanced endocytosis and degradation of EGFR and also reduced downstream phosphoinositide 3-kinase (PI(3)K)-Akt signalling. Phospholipase C ␥1 (PLC␥1) is part of this pathway, being phosphorylated both by EGFR and Akt
We 
identified PLC␥1 as a novel substrate for parkin and report that PLC␥1 interacts with parkin both in dopaminergic neuroblastoma SH-SY5Y cells and in different regions of human brain. Ubiquitination of PLC␥1 is enhanced in parkin WT cells compared to cells expressing the parkin ARJP R42P and G328E mutants. PLC␥1 accumulates in the brains of parkin knockout mice, whereas overexpression of parkin WT in SH-SY5Y cells leads to reduced protein levels of PLC␥1 in comparison to non-transfected (NT) and parkin ARJP mutant cells.

Experimental procedures Human brain and parkin KO mice brain samples
Co-immunoprecipitation
Statistical analyses
Analyses of differences were carried out by ANOVA followed by Fisher's PLSD post hoc test. A value of P Ͻ 0.05 was considered statistically significant. (Fig. 1C) . Quantification of the PLC␥1 band intensity shows that this difference between mouse strains was significant (Fig. 1D ). (Fig. 2A) . The input for this immunoblot is presented as Figure 1A and (Supporting Fig. S1 ). (Fig. 4B) . Quantification of ubiquitin revealed that parkin ARJP mutants had significantly lower levels of PLC␥1 associated ubiquitin (Fig. 4C ). [30] . PKC signalling results in various cellular responses including differentiation, gene expression and apoptosis [31] . Also calcium is central for different cellular processes from regulation of enzyme activity and gene expression to apoptosis [32, 33] . Dopaminergic 
Fig. 1 PLC l levels are decreased in cells overexpressing WT Parkin, and increased in Parkin knockout mice. (A) Immunoblotting of parkin, PLC␥1 and PLC␤ levels in cell lysates from SH-SY5Y cells transfected with parkin (WT) and the ARJP parkin mutations R42P and G328E. (B) Quantification of the PLC␥1 levels from the cells in A. Data are expressed as percentage of values for NT cells and represent the mean Ϯ S.D. of four independent experiments (*, P Ͻ 0.05; ANOVA followed by Fisher's PLSD post hoc test). (C) Immunoblots of brain homogenates from wild-type (WT) and parkin knockout mice (KO) using antibodies against PLC␥1, parkin and ␤-actin. (D) Quantification of PLC␥1 levels in WT and
Fig. 2 PLC␥1 is associated with parkin. (A) Lysates from non-transfected (NT) and in stably transfected human SH-SY5Y neuroblastoma cells with wildtype (WT) parkin and the ARJP parkin mutations R42P and G32E were immunoprecipitated with either anti-parkin (upper panel) or anti-PLC␥1 antibodies (middle and lower panels) and detected by Western blotting with anti-PLC␥1, anti-parkin or anti-c-Cbl antibodies. (B) Confocal micrographs of parkin WT, R42P and G328E cells were double stained with anti-parkin (red) and anti-PLC␥1 (green) antibodies. Superimposed images showed co-localization of parkin and PLC␥1 in parkin WT, R42P and G328E cells (yellow
Parkin and PLC␥1 are associated in human cortical, striatal and nigral areas
The observed interaction between parkin and PLC␥1 in human neuroblastoma cells led us to further investigate if the same observations could be seen in human brain material. Since one of the pathological hallmarks of PD is nigral degeneration affecting dopaminergic input to the striatum, we decided to analyse substantia nigra, striatum and cortex. Immunoprecipitation of human brain homogenates showed that the interaction between parkin and PLC␥1 is consistent in all the three examined regions from three different individuals (Fig. 3A). Western blot analysis of the input for the precipitation uncovered a regional difference in protein levels of PLC␥1 and c-Cbl, which were lower in the nigral fractions but present in striatum and cortex (Fig. 3B). Though c-Cbl could be recognized as a co-precipitate to PLC␥1 in the substantia nigra, but persistently at very low levels. This finding suggests that in the substantia nigra parkin may play a stronger regulatory role in regulating PLC␥1 levels than does c-Cbl. A lower molecular weight band was also detected with the PLC␥1 antibody in all the fractions, but more abundant in the substantia nigra.
Parkin WT successfully ubiquitylates PLC␥1 and this function is impaired in parkin ARJP mutants
As previously reported by others, we found that proteasome inhibition by lactacystin results in an accumulation of PLC␥1 (Fig. 4A). One suggested mechanistic impairment caused by parkin ARJP mutations is a deficient E3 ubiquitin ligase activity. To test this function on PLC␥1, we performed an in vitro ubiquitin conjugation assay. Two major bands were detected, corresponding to full length (150 kD) and a highly ubiquitylated PLC␥1 (approximately 200 kD), respectively. Levels of PLC␥1 associated ubiquitin were identified with immunoblotting with a His-tag antibody
Discussion
Parkin mutant ARJP patients have a similar neuropathological profile as the idiopathic disease, making studies on the functions of parkin important for distinguishing PD pathology. How parkin dysfunction participates in ARJP pathogenesis is still under debate, but it is likely that deficient protein ubiquitination by parkin
